Prestige Biopharma Limited
Clinical trials sponsored by Prestige Biopharma Limited, explained in plain language.
A biopharmaceutical company developing biosimilars and novel drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a copycat humira match the original? Results expected Jun 2027 (estimated)
-
Can a targeted antibody slow advanced pancreatic cancer?
Disease control OngoingThis trial tests an experimental antibody, PBP1510, designed to block a protein called PAUF that may help pancreatic cancer grow. The study includes two parts: first, finding a safe dose of PBP1510 alone or with the chemotherapy gemcitabine; second, testing the best dose in a lar…
Phase 1/2 • Sponsor: Prestige Biopharma Limited • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a copycat humira match the original?
Knowledge-focused OngoingThis trial tests whether a single injection of PBP1502, a proposed biosimilar to the arthritis drug Humira, stays in the body the same way as the European and American versions of Humira. Healthy adults aged 18 to 55 receive one of the three injections, and researchers compare dr…
Phase 1 • Sponsor: Prestige Biopharma Limited • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC